
Merritt G Gillilland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5626433/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hyaluronic acid–bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nature Materials, 2020, 19, 118-126.	27.5	370
2	The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis. Cell, 2020, 182, 447-462.e14.	28.9	314
3	Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats. Gastroenterology, 2014, 146, 484-496.e4.	1.3	212
4	Neonatal acquisition of <i>Clostridia</i> species protects against colonization by bacterial pathogens. Science, 2017, 356, 315-319.	12.6	199
5	Functional Characterization of Inflammatory Bowel Disease–Associated Gut Dysbiosis in Gnotobiotic Mice. Cellular and Molecular Gastroenterology and Hepatology, 2016, 2, 468-481.	4.5	189
6	FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. Journal of Clinical Investigation, 2017, 128, 267-280.	8.2	139
7	Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota. Nature Medicine, 2020, 26, 608-617.	30.7	136
8	A potential pathogenic association between periodontal disease and Crohn's disease. JCI Insight, 2021, 6, .	5.0	35
9	Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship. Gut Microbes, 2014, 5, 571-575.	9.8	32
10	Bile acid toxicity in Paneth cells contributes to gut dysbiosis induced by high-fat feeding. JCI Insight, 2020, 5, .	5.0	28
11	Temporal Gut Microbial Changes Predict Recurrent <i>Clostridiodes Difficile</i> Infection in Patients With and Without Ulcerative Colitis. Inflammatory Bowel Diseases, 2020, 26, 1748-1758.	1.9	15